# Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects

> **NCT00706797** · PHASE4 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 141 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** etanercept (EnbrelTM)
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT00706797
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2009-12
- **Final completion:** 2010-05
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2011-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00706797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00706797, "Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00706797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*